[Consensus Document for Severe Asthma in Adults. 2022 Update]

Severe asthma is a heterogeneous syndrome with several clinical variants and often represents a complex disease requiring a specialized and multidisciplinary approach, as well as the use of multiple drugs. The prevalence of severe asthma varies from one country to another, and it is estimated that 50% of these patients present a poor control of their disease. For the best management of the patient, it is necessary a correct diagnosis, an adequate follow-up and undoubtedly to offer the best available treatment, including biologic treatments with monoclonal antibodies. With this objective, this consensus process was born, which began in its first version in 2018, whose goal is to offer the patient the best possible management of their disease in order to minimize their symptomatology. For this 2020 consensus update, a literature review was conducted by the authors. Subsequently, through a two-round interactive Delphi process, a broad panel of asthma experts from SEPAR and the regional pulmonology societies proposed the recommendations and conclusions contained in this document.

Citing Articles

Efficacy Assessment of Biological Treatments in Severe Asthma.

Laorden D, Dominguez-Ortega J, Romero D, Villamanan E, Mariscal-Aguilar P, Granda P J Clin Med. 2025; 14(2).

PMID: 39860330 PMC: 11766327. DOI: 10.3390/jcm14020321.

Evaluation Checklist for the Multidisciplinary Approach to Patients with Asthma or Suspected Asthma in United Airway Disease.

Almonacid C, Ausin P, Villacampa J, Davila I, Pinilla M, Dominguez-Ortega J J Asthma Allergy. 2025; 17:1325-1332.

PMID: 39749283 PMC: 11693853. DOI: 10.2147/JAA.S496193.

Enhancing the Management of Severe Asthma in Spain: The CARABELA Initiative Disclosed.

Crespo-Lessmann A Open Respir Arch. 2024; 7(1):100378.

PMID: 39717138 PMC: 11663956. DOI: 10.1016/j.opresp.2024.100378.

Correlation of gastro-esophageal reflux disease with asthma control and quality of life: a cross-sectional study from a low-middle income country.

Iqbal N, Amirali A, Lail G, Khan M, Sial R, Irfan M Ther Adv Respir Dis. 2024; 18:17534666241297879.

PMID: 39512235 PMC: 11544649. DOI: 10.1177/17534666241297879.

Real-Life Clinical Outcomes of Benralizumab Treatment in Patients with Uncontrolled Severe Asthma and Coexisting Chronic Rhinosinusitis with Nasal Polyposis.

Chiner E, Murcia M, Boira I, Bernabeu M, Esteban V, Martinez-Moragon E J Clin Med. 2024; 13(14).

PMID: 39064286 PMC: 11278437. DOI: 10.3390/jcm13144247.

References

Peters S, Kunselman S, Icitovic N, Moore W, Pascual R, Ameredes B . Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010; 363(18):1715-26. PMC: 3011177. DOI: 10.1056/NEJMoa1008770. View

Tay T, Lee J, Radhakrishna N, Hore-Lacy F, Stirling R, Hoy R . A Structured Approach to Specialist-referred Difficult Asthma Patients Improves Control of Comorbidities and Enhances Asthma Outcomes. J Allergy Clin Immunol Pract. 2017; 5(4):956-964.e3. DOI: 10.1016/j.jaip.2016.12.030. View

Korn S, Bourdin A, Chupp G, Cosio B, Arbetter D, Shah M . Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years. J Allergy Clin Immunol Pract. 2021; 9(12):4381-4392.e4. DOI: 10.1016/j.jaip.2021.07.058. View

Wechsler M, Colice G, Griffiths J, Almqvist G, Skarby T, Piechowiak T . SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. Respir Res. 2020; 21(1):264. PMC: 7550846. DOI: 10.1186/s12931-020-01503-z. View

Eger K, Kroes J, Ten Brinke A, Bel E . Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma-A Real-Life Evaluation. J Allergy Clin Immunol Pract. 2020; 9(3):1194-1200. DOI: 10.1016/j.jaip.2020.10.010. View

Pola-Bibian B, Dominguez-Ortega J, Vila-Nadal G, Entrala A, Gonzalez-Cavero L, Barranco P . Asthma Exacerbations in a Tertiary Hospital: Clinical Features, Triggers, and Risk Factors for Hospitalization. J Investig Allergol Clin Immunol. 2016; 27(4):238-245. DOI: 10.18176/jiaci.0128. View

Perez de Llano L, Cosio B, Domingo C, Urrutia I, Bobolea I, Valero A . Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study. J Allergy Clin Immunol Pract. 2019; 7(7):2277-2283.e2. DOI: 10.1016/j.jaip.2019.01.017. View

Prete A, Bancos I . Glucocorticoid induced adrenal insufficiency. BMJ. 2021; 374:n1380. DOI: 10.1136/bmj.n1380. View

Sheen Y, Kizilbash S, Ryoo E, Wi C, Park M, Abraham R . Relationship between asthma status and antibody response pattern to 23-valent pneumococcal vaccination. J Asthma. 2019; 57(4):381-390. PMC: 6702096. DOI: 10.1080/02770903.2019.1575394. View

10.

Price D, Bjermer L, Bergin D, Martinez R . Asthma referrals: a key component of asthma management that needs to be addressed. J Asthma Allergy. 2017; 10:209-223. PMC: 5536139. DOI: 10.2147/JAA.S134300. View

11.

Yang F, Busby J, Heaney L, Menzies-Gow A, Pfeffer P, Jackson D . Factors Associated with Frequent Exacerbations in the UK Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021; 9(7):2691-2701.e1. DOI: 10.1016/j.jaip.2020.12.062. View

12.

Thomson N, Rubin A, Niven R, Corris P, Siersted H, Olivenstein R . Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial. BMC Pulm Med. 2011; 11:8. PMC: 3045390. DOI: 10.1186/1471-2466-11-8. View

13.

Khatri S, Moore W, Gibson P, Leigh R, Bourdin A, Maspero J . Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2018; 143(5):1742-1751.e7. DOI: 10.1016/j.jaci.2018.09.033. View

14.

Matucci A, Caminati M, Vivarelli E, Vianello A, Micheletto C, Menzella F . COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey. Allergy. 2020; 76(3):871-874. DOI: 10.1111/all.14516. View

15.

Petsky H, Cates C, Kew K, Chang A . Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis. Thorax. 2018; 73(12):1110-1119. DOI: 10.1136/thoraxjnl-2018-211540. View

16.

Carr T, Kraft M . Management of Severe Asthma before Referral to the Severe Asthma Specialist. J Allergy Clin Immunol Pract. 2017; 5(4):877-886. PMC: 5526085. DOI: 10.1016/j.jaip.2017.04.027. View

17.

Mallah N, Turner J, Gonzalez-Barcala F, Takkouche B . Gastroesophageal reflux disease and asthma exacerbation: A systematic review and meta-analysis. Pediatr Allergy Immunol. 2021; 33(1):e13655. DOI: 10.1111/pai.13655. View

18.

Murphy K, Jacobs J, Bjermer L, Fahrenholz J, Shalit Y, Garin M . Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2017; 5(6):1572-1581.e3. DOI: 10.1016/j.jaip.2017.08.024. View

19.

Gonzalez-Romo F, Picazo J, Garcia Rojas A, Labrador Horrillo M, Barrios V, Magro M . [Consensus document on pneumococcal vaccination in adults at risk by age and underlying clinical conditions. 2017 Update]. Rev Esp Quimioter. 2017; 30(2):142-168. View

20.

Nair P, Wenzel S, Rabe K, Bourdin A, Lugogo N, Kuna P . Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017; 376(25):2448-2458. DOI: 10.1056/NEJMoa1703501. View